Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(33.3%)

Phase 4

1(16.7%)

Phase 1

1(16.7%)

N/A

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 2(2)

Phase 4(1)

Phase 1(1)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07337694Not ApplicableNot Yet Recruiting

Exploring the Clinical Value of an AI-Assisted Patient Self-Assessment App for Bowel Preparation: A Multicenter Study

Role: collaborator

NCT04252118Phase 1Unknown

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19

Role: collaborator

NCT02623556Phase 3Completed

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Role: collaborator

NCT02336542Phase 2Completed

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

NCT02901288Phase 4Unknown

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Role: collaborator

NCT02329730Phase 2Completed

Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Role: collaborator

All 6 trials loaded